your market intelligence analyst
Search Results
Edit Save
1,472 results
Targeted Oncology 12/06/2019 16:29
The triplet regimen of the CXCR4 inhibitor BL-8040, pembrolizumab, plus chemotherapy demonstrated high response and disease control rates in patients with metastatic pancreatic adenocarcinoma, according to preliminary findings from the COMBAT/KEYNOTE-202 trial that were announced in a press release from BioLineRx Ltd, the developer of BL-8040.
Targeted Oncology 12/03/2019 15:00
Selumetinib, an oral MEK inhibitor, demonstrated clinical benefit without significant toxicity in adult patients affected by symptomatic neurofibromatosis type 1 (NF1) with associated plexiform neurofibromas (PN), according to Geraldine O’Sullivan Coyne, MD, PhD, in a preconference briefing of the 2019 American Association for Cancer Research–National Cancer Institute–European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, held October 26 to 30, 2019, in Boston, Massachusetts.

Personal Care

Household Products

Business Issues


Companies - Public

Companies - Venture Funded

Information Technologies


Job Titles